| الصين | تركيا | إسبانيا | |
| علاج الخلايا الجذعية لمرض الزهايمر | من $22,000 | من $15,000 | من $20,000 |
Bookimed لا يضيف رسوماً إضافية على أسعار علاج مرض الزهايمر. الأسعار مأخوذة من قوائم الأسعار الرسمية للعيادات. تدفع مباشرة في العيادة مقابل علاجك عند وصولك إلى البلد.
Bookimed ملتزم بسلامتك. نحن نعمل فقط مع المؤسسات الطبية التي تحافظ على معايير دولية عالية في علاج مرض الزهايمر ولديها التراخيص اللازمة لخدمة المرضى الدوليين في جميع أنحاء العالم.
Bookimed يقدم مساعدة خبراء مجانية. منسق طبي شخصي يدعمك قبل وأثناء وبعد العلاج، ويحل أي مشاكل. لن تكون وحيداً أبداً في رحلة علاج مرض الزهايمر.
البروفيسور تشنغ وي هونغ هو مدير قسم طب الأعصاب وقائد التخصص. شغل سابقًا منصب مدير قسم الأعصاب في مستشفى تشونغشان التابع لجامعة شيامن. وهو أستاذ بجامعة شيامن ومشرف على طلاب الماجستير.
يركّز عمله السريري على الاستقصاء السببي والوقاية وعلاج احتشاء الدماغ والنزف الدماغي. كما يشخّص ويعالج الأمراض العصبية المعقّدة، بما فيها الصرع، والاضطرابات العصبية‑المناعية والعصبية‑العضلية (الوهن العضلي الوبيل، التصلّب المتعدد)، ومرض باركنسون.
العضويات والمناصب: عضو في مجموعة علم المناعة العصبية (فرع طب الأعصاب بالجمعية الطبية الصينية)، وفرع علم المناعة (جمعية السكتة الدماغية الصينية)، ولجنة ترميم الجهاز العصبي (رابطة الأطباء الصينية)، ولجنة اضطرابات الإدراك (الجمعية الصينية لطب المسنين). عضو باللجنة الدائمة للجنة خبراء المستشفيات القاعدية لمشروع فحص السكتة الدماغية والوقاية منها (وزارة الصحة). عضو مجموعة خبراء طب الأعصاب بمركز فوجيان الإقليمي لمراقبة جودة الرعاية الطبية للسكتة والصرع. مدير دائم بجمعية مكافحة الصرع في فوجيان. نائب قائد مجموعة الصرع وتخطيط الدماغ الكهربائي (فرع طب الأعصاب بالجمعية الطبية في فوجيان). نائب رئيس الدورة الأولى للجنة فرع أطباء الأعصاب (رابطة الأطباء في فوجيان). عضو اللجنة الدائمة (الدورات الخامسة–السابعة) لفرع طب الأعصاب (الجمعية الطبية في فوجيان). نائب رئيس اللجنة المتخصصة لطب الأعصاب (الجمعية الطبية في شيامن).
طبيب أعصاب بارز ودكتور في العلوم الطبية مع تدريب ما بعد الدكتوراه في جامعة هارفارد ومؤسسات مرموقة أخرى.
Alzheimer’s disease treatment in China is safe when patients choose accredited tertiary facilities like Dr. Eber Brain Hospital. These centers employ specialists with training from Harvard and UT. Standard protocols include globally approved monoclonal antibodies. Patients must prioritize JCI or ISO-certified hospitals to ensure Western-level safety standards.
Bookimed Expert Insight: While many seek low-cost options, safety in China is tied to academic credentials rather than price. Our data shows that top-performing neurologists, such as Dr. Zheng Wei Hong, often hold dual roles as university professors and committee members for the Ministry of Health. Selecting a doctor with these institutional ties ensures the treatment follows national safety guidelines and uses verified pharmaceutical chains.
Patient Consensus: Patients emphasize the need for independent medical translators to bridge language gaps in public hospitals. They also recommend verifying clinical trial data before traveling for any experimental stem cell procedures.
Alzheimer treatment in China includes anti-amyloid monoclonal antibodies like Lecanemab and unique domestic medications such as Sodium Oligomannate. Specialized centers provide stem cell therapy and neurostimulation. These modalities target amyloid plaques, gut microbiome regulation, and cognitive rehabilitation within modern tertiary-level facilities.
Bookimed Expert Insight: Leading neurologists like Dr. Shao Ming at Dr. Eber Brain Hospital often bring prestigious international training from Harvard and the University of Texas to Chinese treatment protocols. This background allows them to combine domestic drug innovations with Western diagnostic precision in complex neurology cases. Patients should look for doctors with such global credentials when seeking advanced neurophysiological monitoring.
Patient Consensus: Patients note that standard drugs are easily accessible in major cities, but emphasize that integrated TCM approaches like acupuncture often work best when combined with Western medicine. Families suggest focusing on Tier-1 city hospitals to ensure access to authentic medications and avoid counterfeit risks.
Eligibility for Alzheimer’s therapy depends on a clinical diagnosis of mild cognitive impairment or early-stage dementia. Patients must prove amyloid-positive status via PET scans or cerebrospinal fluid analysis. While guidelines focus on adults aged 50 to 90, cognitive stage and overall health outweigh biological age.
Bookimed Expert Insight: Focus on tertiary centers in tier-1 cities like Beijing or Tianjin for complex diagnostics. Dr. Eber Brain Hospital in Tianjin features 63 departments specializing in neurological restoration. Specialized neurologists like Dr. Shao Ming at this facility have extensive international research experience in memory impairment. This high level of specialization is critical because general hospitals may delay the biomarkers testing required for early treatment.
Patient Consensus: Patients emphasize that the diagnosis process often takes over a year. Many regret waiting and advise seeking a neurologist immediately rather than relying on primary care visits. They note that being proactive with amyloid testing is the only way to catch the narrow window for newer therapies.
Patients should anticipate gastrointestinal distress or neurological changes from Alzheimer’s medications in China. Newer amyloid-targeting antibodies like lecanemab carry a 9.4% risk of microhemorrhages. Symptom-relieving drugs often cause nausea or insomnia. Specialized monitoring helps manage these risks safely within Chinese clinical settings.
Bookimed Expert Insight: Coordination of care is vital when combining Western drugs with Traditional Chinese Medicine (TCM). Our data shows that top neurologists like Dr. Zheng Wei Hong at Xiamen Humanity Hospital specialize in both cognitive impairment and neuroimmunology. This dual expertise is crucial because internal research suggests herbal combinations can sometimes lead to unpredictable bleeding risks or increased sedation when used alongside standard prescriptions. We recommend patients verify all medications through hospital pharmacies to ensure authenticity and safety.
Patient Consensus: Many families report being surprised by heart rate drops or fainting. They emphasize the need to start with low doses and verify all medications at hospital pharmacies to avoid quality issues.
International patients typically stay in China for 1 to 4 weeks for initial Alzheimer’s evaluation and therapy. This period covers specialized biomarker testing and neuroimaging. It also includes the start of protocols like stem cell therapy or specific localized drug monitoring. Professional medical support is essential for communication.
Bookimed Expert Insight: While small clinics may offer 10-day diagnostic windows, quaternary centers like Dr. Eber Brain Hospital operate with over 400 doctors across 63 departments. This massive scale often means internal coordination takes longer but provides more thorough results. A 4-week stay is actually safer for patients traveling long distances to manage any initial treatment side effects.
Patient Consensus: Patients emphasize budgeting 6 weeks to avoid rushed protocols and account for potential language barriers. Many suggest securing travel insurance that covers experimental treatments to handle unexpected extensions or observation needs.
Continuing Alzheimer medication from China depends on local drug approval and customs rules. Globally approved drugs like Lecanemab are often transferable. However, China-specific treatments like Oligomannate or stem cell therapy protocols require a local neurologist assessment for long-term care in your home country.
Bookimed Expert Insight: While China leads in neurorestorative research at facilities like Dr. Eber Brain Hospital, these advanced protocols often differ from Western standards. Our data shows that doctors like Dr. Zheng Wei Hong emphasize a transition period where home doctors perform fresh bloodwork before re-prescribing. Do not assume your home neurologist will continue a Chinese protocol without first reviewing these specific clinical records.
Patient Consensus: Patients note that keeping medications in original containers with English labels is vital for passing customs. Many recommend coordinating with a local neurologist before leaving China to avoid gaps in daily treatment.
Clinical follow-up for Alzheimer's treatment in China typically involves virtual monitoring rather than mandatory in-person tests. Patients should prioritize rest and hydration before traveling home. Standard medical evaluations by a local neurologist are recommended within 1 to 3 months to track cognitive progress objectively.
Bookimed Expert Insight: Chinese neurology centers like Dr. Eber Brain Hospital emphasize multidisciplinary approaches including rehabilitation. Because international data coordination is limited, patients should record their own baseline metrics before treatment. This creates a clear benchmark for local doctors to measure post-treatment improvements in motor function or memory.
Patient Consensus: Patients note that formal follow-up is often just a brief video call or phone quiz. Many recommend using independent cognitive apps and private scans at home to verify any neural changes described by the clinic.